Can shorts sink CTIX? I think not. The company has funding through about next June. By that time there should be major news from at least one of the drugs. We should have a move to Phase 2 on Kevetrin, some more information on Brilacidin, at least some kind of preliminary information on Brilacidin-OM (for oral mucositis), and maybe something from Prurisol by then.
If we have more results on Brilacidin or Brilacidin-OM pretty soon, there should be a partnership deal. That will squelch all financial concerns for the company.
I think most people do not truly understand: it is hard to envision a circumstance in which Brilacidin would not be approved. It is as or more effective than the current standard of care, in one dose instead of 7. Therefore there is not a compliance problem, with patients failing to return for folllow-up doses. The side effects have been mild and reversible. It is a totally NEW class of antibiotics, and while I personally believe that the mechanism of action makes development of drug resistance unlikely, right now this new class of antibiotics will have no bacteria that have developed resistance to it, because they've never been exposed to it before.. It's going to be like the first patients to get penicillin -- because the bacteria had no resistance to it, penicillin was incredibly effective in what we would now consider to be very low doses.
Brilacidin-OM -- a wild card. We don't know if it will really work as well as we hope to prevent and treat oral mucositis. BUT, there is no treatment that works well now, so even moderate efficacy should be strong evidence for FDA approval. Of course, since we have no human results yet, we can only speculate as to efficacy.
Kevetrin: so safe that we haven't reached maximum tolerated dose. Even in this very cautious, slow-moving trial (remember how tiny the initial doses were?) there is still some evidence of efficacy. We know about the Stage 4 terminal cancer patient whose metastatic lesion disappeared; we know about the patient in today's press release who experienced some efficacy on a thymus tumor. I just do not believe that the CEO of a company would release such information if there was not much more information that he has that seems promising for this drug. Remember that he stated that "proof of efficacy was presented to the FDA."
We know nothing about whether Prurisol will be effective on psoriasis in humans. We should be finding out fairly soon, since clinical trials are beginning. We know that it cures or at least is a very effective treatment for mice with psoriasis, and was effective on the human tissue which was grafted onto mice. This to me is the big wild card. Will it work on humans, safely? We'll know fairly soon.
So no, I do not think the company will fail because a gang of shorters has conspired to knock this stock down. Many of us have speculated as to their short-term and long-term motives. But I think they have misjudged who they are dealing with, and the strength of the science.
Science will prevail.
If we have more results on Brilacidin or Brilacidin-OM pretty soon, there should be a partnership deal. That will squelch all financial concerns for the company.
I think most people do not truly understand: it is hard to envision a circumstance in which Brilacidin would not be approved. It is as or more effective than the current standard of care, in one dose instead of 7. Therefore there is not a compliance problem, with patients failing to return for folllow-up doses. The side effects have been mild and reversible. It is a totally NEW class of antibiotics, and while I personally believe that the mechanism of action makes development of drug resistance unlikely, right now this new class of antibiotics will have no bacteria that have developed resistance to it, because they've never been exposed to it before.. It's going to be like the first patients to get penicillin -- because the bacteria had no resistance to it, penicillin was incredibly effective in what we would now consider to be very low doses.
Brilacidin-OM -- a wild card. We don't know if it will really work as well as we hope to prevent and treat oral mucositis. BUT, there is no treatment that works well now, so even moderate efficacy should be strong evidence for FDA approval. Of course, since we have no human results yet, we can only speculate as to efficacy.
Kevetrin: so safe that we haven't reached maximum tolerated dose. Even in this very cautious, slow-moving trial (remember how tiny the initial doses were?) there is still some evidence of efficacy. We know about the Stage 4 terminal cancer patient whose metastatic lesion disappeared; we know about the patient in today's press release who experienced some efficacy on a thymus tumor. I just do not believe that the CEO of a company would release such information if there was not much more information that he has that seems promising for this drug. Remember that he stated that "proof of efficacy was presented to the FDA."
We know nothing about whether Prurisol will be effective on psoriasis in humans. We should be finding out fairly soon, since clinical trials are beginning. We know that it cures or at least is a very effective treatment for mice with psoriasis, and was effective on the human tissue which was grafted onto mice. This to me is the big wild card. Will it work on humans, safely? We'll know fairly soon.
So no, I do not think the company will fail because a gang of shorters has conspired to knock this stock down. Many of us have speculated as to their short-term and long-term motives. But I think they have misjudged who they are dealing with, and the strength of the science.
Science will prevail.
